Skip to main content
SP5007,785.76-0.17%DOW53,732.41-0.20%NASDAQ26,729.16-0.28%BTC$62,945.00-0.85%ETH$1,880.32-0.35%GOLD$4,432.00+0.26%OIL$82.40+1.42%
Smart Investors Daily
Sign InSign Up Free
KD

NASDAQ · KDNY

Chinook Therapeutics, Inc.

Healthcare · Biotechnology

$40.39

Up+$0.09 (+0.22%)

Updated Aug 15, 2026, 8:18 AM

SID Score

—

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
2.71B
P/E ratio
-14.08
Dividend yield
0.00%
52-week range
— – —
Volume
3.28M
Avg. volume
2.05M

Price performance

KDNY price history

1M range · 0 trading sessions · Daily adjusted prices

KDNY does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest KDNY news

The latest Smart Investors Daily articles mentioning KDNY.

Stock researchCompany · Overview

KDNY research

Overview

Company profile and research snapshot.

Company profile

Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$30.00
Implied upside
—
Analysts
—
KDNY recent ratings
DateFirmRatingTarget
Aug 8, 2023WedbushNeutral—
Aug 1, 2023Wells FargoEqual-Weight—
Jun 21, 2023HC Wainwright & Co.Neutral—
Jun 14, 2023Evercore ISI GroupIn-Line—
Jun 13, 2023StifelHold—
Open full forecast

News briefing

No generated briefing is available yet.

Benzinga · Aug 1, 2023

Expert Ratings for Chinook Therapeutics

Analysts have provided the following ratings for Chinook Therapeutics (NASDAQ:KDNY) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 2 8 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 7 0 0 3M Ago 0 2 0 0 0 These 10 analysts have an average price target of $39.0 versus the current price of Chinook Therapeutics at $39.18, implying downside. Below is a summary of how these 10 analysts rated Chinook Therapeutics over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of ...Full story available on Benzinga.com

GlobeNewswire Inc. · Jun 17, 2023

Chinook Therapeutics Presents Data from CHK-336 Phase 1 Trial in Healthy Volunteers and New Insights into the Role of Failed Repair in Chronic Kidney Disease at the 60th European Renal Association (ERA) Congress

SEATTLE, June 17, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, announced a free communication presentation on CHK-336 presented today at the 60th ERA Congress being held virtually and live in Milan, Italy.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By